Why is Anktiva so hard to find? [Explained for 2026]

Why Is Anktiva So Hard to Find?

If you or a loved one has been prescribed Anktiva (nogapendekin alfa inbakicept-pmln) for bladder cancer, you may have already discovered that getting this medication isn't straightforward. You're not alone — many patients across the country are struggling to access this first-in-class immunotherapy.

In this guide, we'll break down the reasons why Anktiva is so hard to find in 2026 and give you practical steps to get the treatment you need.

What Is Anktiva and Why Is It Important?

Anktiva is a groundbreaking cancer immunotherapy approved by the FDA in April 2024. It's the first IL-15 superagonist ever approved for medical use. It works by supercharging your immune system — specifically your natural killer cells and T cells — to recognize and destroy bladder cancer cells.

Anktiva is approved for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). For many patients, it represents a chance to avoid having their bladder removed (a surgery called a cystectomy). In clinical trials, Anktiva plus BCG eliminated cancer in more than 62% of patients.

The catch? Anktiva must be used in combination with BCG — and that's where the problems begin.

Reason #1: The Ongoing BCG Shortage

The biggest barrier to accessing Anktiva treatment isn't actually Anktiva itself — it's BCG (Bacillus Calmette-Guérin). BCG is a standard treatment for early-stage bladder cancer and a required companion therapy for Anktiva.

Here's the problem: Merck remains the sole supplier of BCG (TICE BCG) in the United States, and there has been a severe shortage for years. This shortage worsened in 2025 and continues into 2026. Without BCG, doctors cannot administer Anktiva.

ImmunityBio, the company behind Anktiva, is developing a recombinant BCG (rBCG) to help address the shortage. They anticipated making over 45,000 vials available in 2025. However, the shortage remains a significant bottleneck for treatment access.

Reason #2: Specialty Distribution Only

Unlike a typical prescription you'd pick up at your local pharmacy, Anktiva is a specialty medication. It's distributed only through specialty distributors like Cencora (formerly AmerisourceBergen). Your doctor's office or treatment center orders it directly — you can't walk into a CVS or Walgreens and fill this prescription.

This means access depends heavily on your healthcare provider's relationship with the specialty distributor and their ability to manage the buy-and-bill process.

Reason #3: Insurance and Prior Authorization Hurdles

Anktiva carries a wholesale acquisition cost (WAC) of about $35,800 per dose. A full course of treatment (induction plus maintenance over up to 37 months) can cost between $750,000 and $1 million or more.

While insurance coverage has been expanding since the permanent J-code (J9028) was issued in January 2025, getting coverage approved isn't automatic. Most insurers require:

• Prior authorization before treatment can begin
• Documentation proving the patient has BCG-unresponsive NMIBC
• Medical records showing previous BCG treatment failure

Denials and delays are common, especially with newer medications. If your claim is denied, don't give up — appeal processes exist and the ImmunityBio CARE program can help.

Reason #4: Limited Prescribing Specialists

Anktiva is prescribed almost exclusively by urologic oncologists and urologists who specialize in bladder cancer. Not every urology practice has experience with this medication or the infrastructure to administer intravesical treatments with it.

If you live in a rural area or a region without a major cancer center, finding a provider who can prescribe and administer Anktiva may require traveling. For help finding a specialist, check out our guide on how to find a doctor who can prescribe Anktiva near you.

Reason #5: It's a New Medication

Anktiva was only approved in April 2024, making it less than two years old on the market. New specialty oncology medications always face early access challenges:

• Some insurers are still finalizing coverage policies
• Not all treatment centers have established ordering processes
• Provider awareness and comfort level varies

The good news is that adoption is growing rapidly. ImmunityBio reported 700% year-over-year revenue growth for Anktiva in 2025, driven by repeat prescribing and growing physician confidence.

What You Can Do Right Now

If you're having trouble accessing Anktiva, here are concrete steps you can take:

1. Call the ImmunityBio CARE program at 1-877-ANKTIVA (1-877-265-8482). They provide benefits investigation, prior authorization support, and can help with claim denials.
2. Ask about financial assistance. Commercially insured patients may pay as little as $100 per dose through the copay assistance program. Uninsured or underinsured patients may qualify for the patient assistance program.
3. Use MedFinder to locate availability. Visit MedFinder.com to search for Anktiva in stock near you.
4. Request a specialist referral. If your current urologist doesn't prescribe Anktiva, ask for a referral to a urologic oncologist at a larger cancer center.
5. Don't accept the first denial. If insurance denies coverage, file an appeal. The CARE program can assist with payer-specific appeal strategies.

For more detailed tips, read our guide on how to find Anktiva in stock near you.

Looking Ahead: Will Access Improve?

There are reasons to be optimistic about Anktiva access improving over time:

• ImmunityBio is working to resolve the BCG shortage with its recombinant BCG
• Insurance coverage continues to expand across more states and payers
• The European Medicines Agency has recommended conditional marketing authorization, expanding global access
• More treatment centers are gaining experience with the medication

In the meantime, being proactive and using the resources available to you is the best way to overcome the current access barriers.

Related Articles

• How to Find Anktiva in Stock Near You (Tools + Tips)
• Anktiva Shortage Update: What Patients Need to Know in 2026
• Alternatives to Anktiva If You Can't Fill Your Prescription
• How to Save Money on Anktiva in 2026